Apellis Pharmaceuticals has been granted a patent for cell-reactive compstatin analogs to treat complement-mediated disorders. The method involves administering long-acting compstatin analogs intravitreally for eye disorders like geographic atrophy. The analogs consist of PEG with specific molecular weight and amino acid sequences. GlobalData’s report on Apellis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Apellis Pharmaceuticals, Cyclosporin derivatives was a key innovation area identified from patents. Apellis Pharmaceuticals's grant share as of February 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of complement-mediated eye disorder with long-acting compstatin analog
A recently granted patent (Publication Number: US11903994B2) discloses a method for treating complement-mediated eye disorders, specifically geographic atrophy. The method involves intravitreally administering a long-acting compstatin analog (LACA) to the eye of the subject. The LACA consists of a PEG with an average molecular weight of 40 kD attached to two compstatin analog moieties, each comprising a cyclic peptide sequence extended by a lysine residue separated by an AEEAc spacer. The administration of about 15 mg of LACA monthly or every other month is recommended for effective treatment.
Furthermore, the patent claims specify additional details regarding the administration of LACA, including the use of thin-walled needles ranging from 25 to 29 gauge for intravitreal injections. The LACA is to be administered in a concentration of about 150 mg/mL and in a volume of approximately 100 µL. The method outlined in the patent aims to provide a precise and effective treatment for complement-mediated eye disorders, offering a potential solution for patients in need of such therapy, particularly those suffering from geographic atrophy.
To know more about GlobalData’s detailed insights on Apellis Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
